{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:12:10Z","timestamp":1788952330147,"version":"build-2803163510"},"reference-count":69,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Apolipoprotein E (APOE) genotypes, amyloid burden, and relative cerebral perfusion surrogate provide crucial insights into Alzheimer\u2019s disease pathophysiology. This study aimed to investigate the effects of APOE \u03b54 on relative perfusion and amyloid deposition in cognitively normal individuals using dual-phase\n                      <jats:sup>18<\/jats:sup>\n                      F-florbetaben PET.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Cognitively normal subjects who underwent dual-phase\n                      <jats:sup>18<\/jats:sup>\n                      F-FBB PET and APOE genotyping were included. Participants carrying at least one \u03b54 allele were classified as carriers. Standardized uptake value ratios (SUVRs) were analyzed for relative perfusion and amyloid deposition using early phase\n                      <jats:sup>18<\/jats:sup>\n                      F-florbetaben (eFBB) and delayed-phase FBB (dFBB), respectively, in the composite region, including the frontal, parietal, temporal, and occipital cortices, as well as the precuneus, cingulate, and striatum. Target subregions comprised the frontal, parietal, temporal, and occipital cortices along with the precuneus. Correlations between eFBB and dFBB SUVRs were also examined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      APOE \u03b54 carriers exhibited significantly higher relative perfusion in the composite region (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.0042), frontal cortex (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.0054), and parietal cortex (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.0056). Increased amyloid burden was observed in the composite region (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.0065), frontal cortex (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.0028) and precuneus (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.0071). Moreover, eFBB and dFBB SUVRs were significantly positively correlated in the temporal cortex (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.0007) and precuneus (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.0080).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      APOE \u03b54 may be associated with distinct patterns of increased amyloid deposition and relative perfusion in specific brain regions in cognitively normal individuals. Dual-phase\n                      <jats:sup>18<\/jats:sup>\n                      F-FBB PET may provide complementary information on Alzheimer\u2019s disease-related changes in APOE \u03b54 carriers during the preclinical stage.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002186","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:00:19Z","timestamp":1780383619000},"page":"1196-1206","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effects of apolipoprotein E \u03b54 on amyloid deposition and relative cerebral perfusion in cognitively normal individuals: a dual-phase 18F-florbetaben PET study"],"prefix":"10.1097","volume":"47","author":[{"given":"Ji-Young","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Ewha Womans University, College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghyeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Research Institute, Neurophet Incorporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geon Ha","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ewha Womans University, College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8752-6280","authenticated-orcid":false,"given":"Hai-Jeon","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ewha Womans University, College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"R1-20260909","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/alz.12190","article-title":"Alzheimer\u2019s & Dementia: the journal of the Alzheimer\u2019s Association.","volume":"17","author":"Mecca","year":"2021","journal-title":"Alzheimers Dement"},{"key":"R2-20260909","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease.","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"key":"R3-20260909","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamaneurol.2020.3780","article-title":"Association between apolipoprotein E \u03b52 vs \u03b54, Age, and \u03b2-amyloid in adults without cognitive impairment.","volume":"78","author":"Insel","year":"2021","journal-title":"JAMA Neurology"},{"key":"R4-20260909","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"R5-20260909","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1212\/WNL.0000000000004336","article-title":"APOE genotype and early beta-amyloid accumulation in older adults without dementia.","volume":"89","author":"Lim","year":"2017","journal-title":"Neurology"},{"key":"R6-20260909","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jalz.2018.02.009","article-title":"Prevalence of the apolipoprotein E epsilon4 allele in amyloid beta positive subjects across the spectrum of Alzheimer\u2019s disease.","volume":"14","author":"Mattsson","year":"2018","journal-title":"Alzheimers Dement"},{"key":"R7-20260909","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","article-title":"Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease.","volume":"41","author":"Harold","year":"2009","journal-title":"Nat Genet"},{"key":"R8-20260909","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families.","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"R9-20260909","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1212\/01.WNL.0000129533.26544.BF","article-title":"Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele.","volume":"62","author":"Caselli","year":"2004","journal-title":"Neurology"},{"key":"R10-20260909","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1148\/radiol.2018170575","article-title":"Alzheimer disease and mild cognitive impairment: integrated pulsed arterial spin-labeling MRI and (18)F-FDG PET.","volume":"288","author":"Riederer","year":"2018","journal-title":"Radiology"},{"key":"R11-20260909","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","article-title":"Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: a multicentre phase 2 diagnostic study.","volume":"10","author":"Barthel","year":"2011","journal-title":"Lancet Neurol"},{"key":"R12-20260909","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1007\/s12035-015-9388-7","article-title":"Multiple effect of APOE genotype on clinical and neuroimaging biomarkers across Alzheimer\u2019s disease spectrum.","volume":"53","author":"Liu","year":"2016","journal-title":"Mol Neurobiol"},{"key":"R13-20260909","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease.","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"R14-20260909","first-page":"2470","article-title":"Abeta-clearing drug fails to slow Alzheimer disease.","volume":"319","author":"Slomski","year":"2018","journal-title":"JAMA"},{"key":"R15-20260909","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"R16-20260909","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMoa0809437","article-title":"Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect.","volume":"361","author":"Caselli","year":"2009","journal-title":"N Engl J Med"},{"key":"R17-20260909","doi-asserted-by":"crossref","first-page":"e27415","DOI":"10.1371\/journal.pone.0027415","article-title":"The association of APOE genotype with cognitive function in persons aged 35 years or older.","volume":"6","author":"Izaks","year":"2011","journal-title":"PLoS One"},{"key":"R18-20260909","doi-asserted-by":"crossref","first-page":"104784","DOI":"10.1016\/j.nbd.2020.104784","article-title":"APOE-amyloid interaction: therapeutic targets.","volume":"138","author":"Wisniewski","year":"2020","journal-title":"Neurobiol Dis"},{"key":"R19-20260909","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"R20-20260909","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","article-title":"Imaging of amyloid beta in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.","volume":"7","author":"Rowe","year":"2008","journal-title":"Lancet Neurol"},{"key":"R21-20260909","first-page":"594","article-title":"Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging.","volume":"45","author":"Silverman","year":"2004","journal-title":"J Nucl Med"},{"key":"R22-20260909","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/ph14020110","article-title":"Tauvid\u2122: the first FDA-approved PET tracer for imaging tau pathology in Alzheimer\u2019s disease.","volume":"14","author":"Jie","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"R23-20260909","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJM199603213341202","article-title":"Preclinical evidence of Alzheimer\u2019s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.","volume":"334","author":"Reiman","year":"1996","journal-title":"N Engl J Med"},{"key":"R24-20260909","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","article-title":"Relationships between biomarkers in aging and dementia.","volume":"73","author":"Jagust","year":"2009","journal-title":"Neurology"},{"key":"R25-20260909","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2967\/jnumed.108.051946","article-title":"Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern?","volume":"49","author":"Sojkova","year":"2008","journal-title":"J Nucl Med"},{"key":"R26-20260909","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s00330-015-3834-9","article-title":"Cerebral perfusion in the predementia stages of Alzheimer\u2019s disease.","volume":"26","author":"Binnewijzend","year":"2016","journal-title":"Eur Radiol"},{"key":"R27-20260909","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/HYPERTENSIONAHA.118.10900","article-title":"Dynamic regulation of cerebral blood flow in patients with Alzheimer\u2019s disease.","volume":"72","author":"de Heus","year":"2018","journal-title":"Hypertension"},{"key":"R28-20260909","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2967\/jnumed.123.266273","article-title":"Early-frame [(18)F]florbetaben PET\/MRI for cerebral blood flow quantification in patients with cognitive impairment: comparison to an [(15)O]water gold standard.","volume":"65","author":"Fettahoglu","year":"2024","journal-title":"J Nucl Med"},{"key":"R29-20260909","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1007\/s00259-016-3353-1","article-title":"Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer\u2019s disease.","volume":"43","author":"Tiepolt","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R30-20260909","doi-asserted-by":"crossref","first-page":"18480","DOI":"10.1038\/s41598-024-68916-4","article-title":"Elevated cerebral blood flow proxy with increased beta-amyloid burden in Alzheimer\u2019s disease preclinical phase evaluated by dual-phase (18)F-florbetaben positron emission tomography.","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"key":"R31-20260909","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00401-020-02215-w","article-title":"Cerebral blood flow decrease as an early pathological mechanism in Alzheimer\u2019s disease.","volume":"140","author":"Korte","year":"2020","journal-title":"Acta Neuropathol"},{"key":"R32-20260909","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jmri.26810","article-title":"Increased cerebral blood flow with increased amyloid burden in the preclinical phase of Alzheimer\u2019s disease.","volume":"51","author":"Fazlollahi","year":"2020","journal-title":"J Magn Reson Imaging"},{"key":"R33-20260909","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1177\/0271678X231178993","article-title":"Genetic, vascular and amyloid components of cerebral blood flow in a preclinical population.","volume":"43","author":"Padrela","year":"2023","journal-title":"J Cereb Blood Flow Metab"},{"key":"R34-20260909","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3233\/JAD-132252","article-title":"Increased hippocampal blood flow in sedentary older adults at genetic risk for Alzheimer\u2019s disease.","volume":"41","author":"Zlatar","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"R35-20260909","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/0271678X15605847","article-title":"Arterial spin labeling imaging reveals widespread and Abeta-independent reductions in cerebral blood flow in elderly apolipoprotein epsilon-4 carriers.","volume":"36","author":"Michels","year":"2016","journal-title":"J Cereb Blood Flow Metab"},{"key":"R36-20260909","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1177\/0271678X211020863","article-title":"Evidence of cerebral hemodynamic dysregulation in middle-aged APOE epsilon4 carriers: the PREVENT-Dementia study.","volume":"41","author":"Dounavi","year":"2021","journal-title":"J Cereb Blood Flow Metab"},{"key":"R37-20260909","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/diagnostics12030623","article-title":"Development of amyloid PET analysis pipeline using deep learning-based brain MRI segmentation-a comparative validation study.","volume":"12","author":"Lee","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R38-20260909","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1002\/alz.14054","article-title":"Development of a prediction model for cognitive impairment of sarcopenia using multimodal neuroimaging in non-demented older adults.","volume":"20","author":"Kim","year":"2024","journal-title":"Alzheimers Dement"},{"key":"R39-20260909","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3390\/brainsci10120974","article-title":"Split-attention U-net: a fully convolutional network for robust multi-label segmentation from brain MRI.","volume":"10","author":"Lee","year":"2020","journal-title":"Brain Sci"},{"key":"R40-20260909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"key":"R41-20260909","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00259-011-2051-2","article-title":"Correlation of early-phase 18F-florbetapir (AV-45\/Amyvid) PET images to FDG images: preliminary studies.","volume":"39","author":"Hsiao","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R42-20260909","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology.","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"key":"R43-20260909","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","article-title":"Phases of A beta-deposition in the human brain and its relevance for the development of AD.","volume":"58","author":"Thal","year":"2002","journal-title":"Neurology"},{"key":"R44-20260909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hbm.1058","article-title":"Nonparametric permutation tests for functional neuroimaging: a primer with examples.","volume":"15","author":"Nichols","year":"2002","journal-title":"Hum Brain Mapp"},{"key":"R45-20260909","doi-asserted-by":"crossref","first-page":"e68910","DOI":"10.1371\/journal.pone.0068910","article-title":"BrainNet Viewer: a network visualization tool for human brain connectomics.","volume":"8","author":"Xia","year":"2013","journal-title":"PLoS One"},{"key":"R46-20260909","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1172\/JCI124853","article-title":"APOE4-mediated amyloid-beta pathology depends on its neuronal receptor LRP1.","volume":"129","author":"Tachibana","year":"2019","journal-title":"J Clin Invest"},{"key":"R47-20260909","doi-asserted-by":"crossref","first-page":"e1554","DOI":"10.1212\/WNL.0000000000010314","article-title":"Association of education with Abeta burden in preclinical familial and sporadic Alzheimer\u2019s disease.","volume":"95","author":"Gonneaud","year":"2020","journal-title":"Neurology"},{"key":"R48-20260909","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1212\/01.wnl.0000240117.55680.0a","article-title":"Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer\u2019s disease.","volume":"67","author":"Kemppainen","year":"2006","journal-title":"Neurology"},{"key":"R49-20260909","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","article-title":"Imaging beta-amyloid burden in aging and dementia.","volume":"68","author":"Rowe","year":"2007","journal-title":"Neurology"},{"key":"R50-20260909","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fnagi.2018.00304","article-title":"Involvement of the precuneus\/posterior cingulate cortex is significant for the development of Alzheimer\u2019s disease: a PET (THK5351, PiB) and resting fMRI study.","volume":"10","author":"Yokoi","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"R51-20260909","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ana.410420114","article-title":"Metabolic reduction in the posterior cingulate cortex in very early Alzheimer\u2019s disease.","volume":"42","author":"Minoshima","year":"1997","journal-title":"Ann Neurol"},{"key":"R52-20260909","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/jnnp.60.6.644","article-title":"SPECT and MRI analysis in Alzheimer\u2019s disease: relation to apolipoprotein E epsilon 4 allele.","volume":"60","author":"Lehtovirta","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R53-20260909","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/jnnp.64.6.742","article-title":"Longitudinal SPECT study in Alzheimer\u2019s disease: relation to apolipoprotein E polymorphism.","volume":"64","author":"Lehtovirta","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R54-20260909","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/089198870101400110","article-title":"Single photon emission computed tomography and apolipoprotein E in Alzheimer\u2019s disease: impact of the epsilon4 allele on regional cerebral blood flow.","volume":"14","author":"Hogh","year":"2001","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"R55-20260909","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1177\/0271678X20935171","article-title":"Regional hyperperfusion in older adults with objectively-defined subtle cognitive decline.","volume":"41","author":"Thomas","year":"2021","journal-title":"J Cereb Blood Flow Metab"},{"key":"R56-20260909","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/CIA.S58879","article-title":"Pattern of cerebral hyperperfusion in Alzheimer\u2019s disease and amnestic mild cognitive impairment using voxel-based analysis of 3D arterial spin-labeling imaging: initial experience.","volume":"9","author":"Ding","year":"2014","journal-title":"Clin Interv Aging"},{"key":"R57-20260909","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nn.2801","article-title":"Neuronal activity regulates the regional vulnerability to amyloid-beta deposition.","volume":"14","author":"Bero","year":"2011","journal-title":"Nat Neurosci"},{"key":"R58-20260909","first-page":"55","article-title":"The effect of APOE \u03b54 allele on brain perfusion SPECT in late onset Alzheimer\u2019s disease by an automated program, 3DSRT.","volume":"6","author":"Seiju Kobayashi","year":"2016","journal-title":"Neuropsychiatry"},{"key":"R59-20260909","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1097\/00001756-199708180-00001","article-title":"Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and alpha1-antichymotrypsin type A allele in Alzheimer\u2019s disease.","volume":"8","author":"Higuchi","year":"1997","journal-title":"Neuroreport"},{"key":"R60-20260909","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3940(98)00673-9","article-title":"Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer\u2019s disease.","volume":"254","author":"Mielke","year":"1998","journal-title":"Neurosci Lett"},{"key":"R61-20260909","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/jnnp-2020-322924","article-title":"Regional hyperperfusion in cognitively normal APOE epsilon4 allele carriers in mid-life: analysis of ASL pilot data from the PREVENT-Dementia cohort.","volume":"91","author":"McKiernan","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R62-20260909","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s40265-025-02250-5","article-title":"Clinical efficacy, safety and imaging effects of oral valiltramiprosate in APOEepsilon4\/epsilon4 homozygotes with early Alzheimer\u2019s disease: results of the phase III, randomized, double-blind, placebo-controlled, 78-week APOLLOE4 trial.","volume":"85","author":"Abushakra","year":"2025","journal-title":"Drugs"},{"key":"R63-20260909","doi-asserted-by":"crossref","first-page":"100269","DOI":"10.1016\/j.tjpad.2025.100269","article-title":"CTAD taskforce: genetic therapies in Alzheimer\u2019s disease.","volume":"12","author":"Jakabek","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"R64-20260909","doi-asserted-by":"crossref","first-page":"16738","DOI":"10.1038\/s41598-021-95808-8","article-title":"Comparison of early F-18 Florbetaben PET\/CT to Tc-99m ECD SPECT using voxel, regional, and network analysis.","volume":"11","author":"Kwon","year":"2021","journal-title":"Sci Rep"},{"key":"R65-20260909","doi-asserted-by":"crossref","first-page":"102773","DOI":"10.1016\/j.nicl.2021.102773","article-title":"Dual-phase (18)F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer\u2019s disease.","volume":"31","author":"Yoon","year":"2021","journal-title":"Neuroimage Clin"},{"key":"R66-20260909","doi-asserted-by":"crossref","first-page":"13365","DOI":"10.1038\/s41598-020-69603-w","article-title":"Distribution and clinical impact of apolipoprotein E4 in subjective memory impairment and early mild cognitive impairment.","volume":"10","author":"Cho","year":"2020","journal-title":"Sci Rep"},{"key":"R67-20260909","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000321984","article-title":"Apolipoprotein E epsilon4 prevalence in Alzheimer\u2019s disease patients varies across global populations: a systematic literature review and meta-analysis.","volume":"31","author":"Crean","year":"2011","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"Pt 4","key":"R68-20260909","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1469-1809.1999.6340301.x","article-title":"Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a \u2018thrifty\u2019 allele?","volume":"63","author":"Corbo","year":"1999","journal-title":"Ann Hum Genet"},{"key":"R69-20260909","first-page":"553","article-title":"Lifestyle, genetics, and disease in Sami.","volume":"47","author":"Ross","year":"2006","journal-title":"Croat Med J"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:21:17Z","timestamp":1788949277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002186","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"2026-01-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}